)
Following United States food and Drug Administration's approval to its abbreviated new drug application (ANDA), Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories Limited has launched Lamotrigine Extended-Release (XR) tablets in the US market on June 25.
Available in 25 mg, 50 mg, 100 mg, 200 mg and 300 mg strengths, Lamotrigine XR is a therapeutic equivalent generic version of Lamictal XR (lamotrigine), which is indicated for the treatment of epilepsy, the company said in press release on Wednesday.
The Lamictal XR brand and generic had combined US sales of approximately $300.5 million for the most-recent 12 months ending in April 2013, according to IMS Health, an information, services and technology provider for the global healthcare industry.
Dr Reddy’s scrip is currently trading at Rs 2,097.65 on the BSE, down 0.11 per cent, over the previous close of Rs 2,099.90 a share.
